<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901689</url>
  </required_header>
  <id_info>
    <org_study_id>ARO_21_018_002</org_study_id>
    <nct_id>NCT04901689</nct_id>
  </id_info>
  <brief_title>Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation</brief_title>
  <official_title>A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoDyn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C&#xD;
      chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis&#xD;
      via leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory&#xD;
      leukocytes and dampen pathogenic immune activation in coronavirus disease 2019 (COVID-19).&#xD;
&#xD;
      The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of&#xD;
      care in critically ill patients hospitalized with COVID-19 pneumonia who are requiring&#xD;
      mechanical ventilation or extracorporeal oxigenation (ECMO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C&#xD;
      chemokine receptor type 5 (CCR5). CCR5 is expressed predominantly on T cells but also found&#xD;
      on macrophages, dendritic cells, and eosinophils to mediate chemotaxis in response to its&#xD;
      cognate ligands that include CCL5 (RANTES), CCL3 (MIP-1α), and CCL4 (MIP-1β). These ligands&#xD;
      are integral in the recruitment of these immune cells to inflammatory sites. The&#xD;
      immunopathogenesis of COVID-19 likely involves the excessive influx of immune cells into the&#xD;
      lung. Disruption of the CCL5-CCR5 axis via leronlimab-mediated CCR5 blockade might prevent&#xD;
      pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation&#xD;
      in COVID-19.&#xD;
&#xD;
      The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of&#xD;
      care in critically ill patients hospitalized with COVID-19 pneumonia who are requiring&#xD;
      mechanical ventilation or extracorporeal oxigenation (ECMO).&#xD;
&#xD;
      This is a Phase 3, 2-arm, randomized, double blind, placebo controlled, multicenter study to&#xD;
      evaluate the safety and efficacy of leronlimab (PRO 140) as an add on therapy to the&#xD;
      institutional standard of care (SoC) for the management of critically ill patients with&#xD;
      COVID-19 pneumonia.&#xD;
&#xD;
      Patients will be randomized in a 1:1 ratio to receive up to four doses of 700 mg leronlimab&#xD;
      (PRO 140) or placebo. Leronlimab or placebo will be administered by 30-minute intravenous&#xD;
      (IV) infusion weekly over a 4-week treatment period. No treatments will be administered&#xD;
      post-discharge.&#xD;
&#xD;
      The participant will be evaluated on each study day while hospitalized up until and including&#xD;
      Day 28. The daily visits will capture clinical status - ordinal scale and the occurrence of&#xD;
      adverse events. A complete follow-up assessment will be performed at Days 7, 14, 21, 28, 42&#xD;
      and 60 for those who are hospitalized at these specific timepoints. Follow-up visits can be&#xD;
      conducted as telephone or video contact visits, if subject is discharged from the hospital&#xD;
      prior to the complete follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative proportion of clinical recovery</measure>
    <time_frame>28 days</time_frame>
    <description>Patients will be considered to have recovered if they attain categories 1, 2, or 3 on the eight-category ordinal scale within 28 days, as follows:&#xD;
Not hospitalized, no limitations on activities&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients clinically recovered</measure>
    <time_frame>At days 14, 28, 42, and 60</time_frame>
    <description>Ordinal Scale of 1, 2 or 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>At days 14, 28, 42, and 60</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients discharged alive</measure>
    <time_frame>At days 14, 28, 42, and 60</time_frame>
    <description>Ordinal Scale 1 or 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status</measure>
    <time_frame>Days 14, 28, 42, and 60</time_frame>
    <description>Ordinal Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive mechanical ventilation or ECMO</measure>
    <time_frame>28 days</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>28 days</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>28 days</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Leronlimab (700 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leronlimab 700 mg intravenously once a week (up to 4 doses) until hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intravenously once a week (up to 4 doses) until hospital discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leronlimab</intervention_name>
    <description>Leronlimab 700 mg</description>
    <arm_group_label>Leronlimab (700 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or females aged ≥ 18 years&#xD;
&#xD;
          2. Critically ill patients with COVID-19 (defined as Ordinal Scale score of 7):&#xD;
             Hospitalized, on invasive mechanical ventilation or extracorporeal membrane&#xD;
             oxygenation (ECMO) for less than 72 hours.&#xD;
&#xD;
          3. Evidence of pneumonia (pulmonary infiltrates) at chest radiography or computed&#xD;
             tomography compatible with COVID-19.&#xD;
&#xD;
          4. Laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by&#xD;
             polymerase chain reaction (PCR).&#xD;
&#xD;
          5. Subject (or legally authorized representative) provides written or oral informed&#xD;
             consent prior to initiation of any study procedures.&#xD;
&#xD;
          6. Women of childbearing potential and their partner must agree to use at least one&#xD;
             highly effective method of contraception (e.g., hormonal contraceptives [implants,&#xD;
             injectables, combination oral contraceptives, transdermal patches, or contraceptive&#xD;
             rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who had been on invasive mechanical ventilation or extracorporeal membrane&#xD;
             oxygenation (ECMO) for &gt;72 hours prior to the screening.&#xD;
&#xD;
          2. Subjects who have a history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to leronlimab (PRO 140) are not eligible.&#xD;
&#xD;
          3. Inability to provide informed consent (from subject or legally authorized&#xD;
             representative) or to comply with test requirements.&#xD;
&#xD;
          4. Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk&#xD;
             associated with study participation or, in the investigator's judgment, make the&#xD;
             participant inappropriate for the study.&#xD;
&#xD;
          5. Pregnancy or breast feeding.&#xD;
&#xD;
          6. Subject participating in another study with for an investigational treatment.&#xD;
&#xD;
          7. Suspected or known active systemic bacterial, fungal, or viral infections (with the&#xD;
             exception of COVID-19), that may increase the risk for the study participant based on&#xD;
             investigator judgement.&#xD;
&#xD;
          8. Participants who are immunocompromised, with known immunodeficiencies, or taking&#xD;
             potent immunosuppressive agents (e.g., azathioprine, cyclosporine).&#xD;
&#xD;
          9. Patients with estimated discharge or transfer for other hospital in the first 72 hours&#xD;
             of study inclusion.&#xD;
&#xD;
         10. Patients with low probability of survival in the first 48 hours of study inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Otavio Berwanger, MD, PhD</last_name>
    <phone>+551121515915</phone>
    <email>otavio.berwanger@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Guimaraes, MD, PhD</last_name>
    <phone>+551121515915</phone>
    <email>patricia.oguimaraes@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilson Feitosa Filho, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital do Coração do Brasil</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Fonseca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Atena de Pesquisa Clínica</name>
      <address>
        <city>Natal</city>
        <state>RN</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Paiva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do Coração</name>
      <address>
        <city>Aracaju</city>
        <state>SE</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Silveira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Misericórdia de Bragança Paulista</name>
      <address>
        <city>Bragança Paulista</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murillo Antunes, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clínica de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Saraiva, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Alemão Oswaldo Cruz</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Sato, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Beneficência Portuguesa</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Veiga, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundação Faculdade Regional de Medicina de São José do Rio Preto</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzana Lobo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Votuporanga</name>
      <address>
        <city>Votuporanga</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Hernandes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remo Furtado, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Leronlimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leronlimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

